What We Do
Transforming Antibody Discovery
Transgenic mice have powered the largest number of successful antibodies to clinic among human platforms, but innovation in transgenic technologies has not kept pace with the increasingly complex needs of buried epitopes, complex targets, or multispecific modalities. AbTherx has built the industry’s most comprehensive toolbox of transgenic technologies for antibody discovery and is continuing to drive evolution of transgenic platforms to address industry needs and create tomorrow’s medicines.
mAbs Targeting Buried Epitopes, GPCRs, and Ion Channels
Hard targets need hard-hitting technology. Our patent-pending Atlas Long CDR3 Mice generate fully human antibodies with long CDR3 regions to unlock access to buried epitopes within GPCRs, ion channels, and other challenging targets. Our innovative platform takes advantage of a rare but naturally -occurring human mechanism whereby two D segments (i.e., a “D-D fusion”) recombine to create a final VD(D)J recombination product. This extra sequence information serves to lengthen the CDRH3 portion of the resultant antibody.
We have harnessed this behavior via a unique transgene configuration to generate fully human antibodies with long CDR3 regions. Being fully human, these minimize developability and immunogenicity risks inherent in long CDR3 antibodies from other species, e.g., bovine and camelids. Our Long CDR3 platform, coupled with our proprietary AI-based immunogen design and expression, can identify and immunize against novel targets and epitopes that may have been buried or otherwise less accessible to traditional humanized models.
Premier Multispecifics
Our innovative, patent-pending Atlas Binary Fixed Light Chain Mice empower our partners to create native-structure bispecific IgGs that facilitate manufacturability and developability, achieve best-in-class hit rates, and advance programs confidently under a strong freedom-to-operate position. This is accomplished by engineering the transgenic mice to include two fixed light chain options, on a background of full human diversity for the heavy chain.The fixed light chains were chosen for their overlapping but distinct abilities to pair with multiple heavy chain families and their high prevalence in human B cell populations. In individual B cells where an either/or selection of the two light chains is made, this model allows for a more natural selection pathway where the best heavy-light chain pairing and binding solutions are achieved.
This model thus improves upon legacy fixed light chain models by providing a larger repertoire, and the native structure makes downstream expression and engineering steps correspondingly straightforward. Importantly, our technology is supported by an agile business model, offering access through milestone- and royalty-free agreements as well as standard licensing options.
Efficient mAb Discovery
Our patent-pending Atlas Full Human Diversity Mice enable our partners to achieve greater success with higher hit rates, greater sequence diversity, improved binding profiles, and enhanced hybridoma stability compared to other top transgenics. Access this industry-leading in vivo discovery platform through Mosaic Biosciences, our preferred service partner. We offer flexible business terms—from milestone- and-royalty free structures to shared risk models where you pay upon success—designed to meet the needs of innovators at every stage.
The Atlas Full Human Diversity Mouse is engineered to capture a broad, human-like antibody response by sourcing VH and VK alleles that represent >99% of the expressed human repertoire, and boosting productive B-cell rearrangements by use of only functional VH and VK components, excluding pseudogenes and other non-productive alleles. The transgenes were carefully curated to avoid patented alleles and rare/ethnic variants that could elevate immunogenicity or IP risk, creating a next-generation platform that improves upon the functional and freedom-to-operate limitations of other models
